Concepedia

Author

Laurent Tessonnier

Hôpital de la Timone

Also Known As

G Habib, L Tessonnier, L. Tessonnier, Laurent Tessonnier, S Cammilleri, Tessonnier, L., Tessonnier, Laurent, V Miller

48

Publications

1.5K

Citations

14

H-Index

41

Concepts

All Affiliations

Hôpital de la TimoneCentre Hospitalier Intercommunal Toulon-La Seyne-sur-MerHôpital Bichat-Claude-BernardInstitut Gustave RoussyUniversité Paris-Sud
LT

About

Laurent Tessonnier is an author at Hôpital de la Timone specializing in medicine, radiology, and pathology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

6

6

117

2

Health Sciences

3

3

141

3

Engineering

1

1

100

4

Public Health

1

1

11

5

Allergy

1

1

25

Laurent Tessonnier

×

15

Publications

1.4K

Citations

13

H-Index

YearCitations

Hyperprogressive Disease in Patients With Advanced Non–Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy

Roberto Ferrara, Laura Mezquita, Matthieu Texier,

JAMA Oncology

2018

719

<sup>18</sup>F-FDG Avidity of Pheochromocytomas and Paragangliomas: A New Molecular Imaging Signature?

David Taïeb, F. Sébag, Anne Barlier,

Journal of Nuclear Medicine

2009

125

Does 18F-FDG PET/CT add diagnostic accuracy in incidentally identified non-secreting adrenal tumours?

Laurent Tessonnier, F. Sébag, Fausto Palazzo,

European Journal of Nuclear Medicine and Molecular Imaging

2008

100

Limited Value of 18F-F-DOPA PET to Localize Pancreatic Insulin-Secreting Tumors in Adults with Hyperinsulinemic Hypoglycemia

Laurent Tessonnier, F. Sébag, C. Ghander,

The Journal of Clinical Endocrinology & Metabolism

2009

83

The role of <sup>18</sup>F‐FDOPA and <sup>18</sup>F‐FDG–PET in the management of malignant and multifocal phaeochromocytomas

David Taïeb, Laurent Tessonnier, F. Sébag,

Clinical Endocrinology

2008

80

Interobserver Agreement of Qualitative Analysis and Tumor Delineation of <sup>18</sup>F-Fluoromisonidazole and 3′-Deoxy-3′-<sup>18</sup>F-Fluorothymidine PET Images in Lung Cancer

S. Thureau, Philippe Chaumet‐Riffaud, Romain Modzelewski,

Journal of Nuclear Medicine

2013

48

<sup>18</sup>F‐FDG Uptake at Initial Staging of the Adrenocortical Cancers: A Diagnostic Tool but Not of Prognostic Value

Laurent Tessonnier, C. Ansquer, Claire Bournaud,

World Journal of Surgery

2012

39

Comparison of Fast-Progression, Hyperprogressive Disease, and Early Deaths in Advanced Non–Small-Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or Chemotherapy

Roberto Ferrara, Laura Mezquita, Matthieu Texier,

JCO Precision Oncology

2020

37

Hyperprogressive disease (HPD) is frequent in non-small cell lung cancer (NSCLC) patients (pts) treated with anti PD1/PD-L1 monoclonal antibodies (IO)

Roberto Ferrara, Caroline Caramella, Matthieu Texier,

Annals of Oncology

2017

28

Adaptive radiotherapy (up to 74 Gy) or standard radiotherapy (66 Gy) for patients with stage III non-small-cell lung cancer, according to [18F]FDG-PET tumour residual uptake at 42 Gy (RTEP7–IFCT-1402): a multicentre, randomised, controlled phase 2 trial

Pierre Véra, S. Thureau, F. Le Tinier,

The Lancet Oncology

2024

28

Page 1